Semax: The ACTH Fragment That Russian Pharmacology Built a Cognitive Drug Around

Ashmarin and the Soviet Pharmacology Tradition

To understand Semax, you have to understand a particular institutional context. The Soviet Union, and then the Russian Federation, maintained a pharmacology research tradition that operated somewhat independently from the Western framework. Drugs were developed, tested, and approved in ways that didn't always map onto FDA-style processes, and clinical evidence accumulated in Russian-language journals that had limited circulation in English-language literature.

Igor Ashmarin was one of the towering figures of Soviet and post-Soviet biochemistry. He spent most of his career at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow. He was interested in regulatory peptides — small bioactive sequences that modulate physiological state — and he and his colleagues spent decades systematically working through fragments of larger peptide hormones to identify subsequences with specific desired activities.

Semax was one of the products of that program. Ashmarin's group started with adrenocorticotropic hormone, ACTH, a 39-amino-acid pituitary peptide whose primary function is stimulating cortisol release from the adrenal cortex. The 4-10 fragment of ACTH (the seven amino acids from position 4 to position 10, sequence Met-Glu-His-Phe-Arg-Trp-Gly) had been known since the 1960s to have CNS effects — improving memory and attention in animal models — without the steroidogenic activity of full-length ACTH. The cortisol release was a side effect researchers wanted to remove. The cognitive activity was what they wanted to preserve.

Ashmarin's group designed a modified version. They replaced the C-terminal Arg-Trp-Gly with Pro-Gly-Pro to stabilize the peptide against proteolytic degradation, and kept the ACTH(4-7) Met-Glu-His-Phe core intact. The result was a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, abbreviated MEHFPGP. They named it Semax. The work went into clinical development in the late 1980s and early 1990s, and Semax received Russian regulatory approval in 1994.

The BDNF Story

The most consistently replicated finding about Semax involves brain-derived neurotrophic factor. BDNF is one of the central neurotrophic factors in the adult brain, supporting neuron survival, synaptic plasticity, and memory consolidation. Levels decline with age and are reduced in several neurological disorders. Compounds that elevate BDNF expression are of substantial pharmacological interest.

Dolotov, Karpenko, Levitskaya and colleagues, working in Ashmarin's institutional descendant lab, published a series of papers through the 2000s in journals including Brain Research and Molecular Psychiatry. The findings were consistent: Semax administered intranasally to rats produced rapid (within 30 minutes) and substantial (2-3 fold) elevation of BDNF mRNA expression in the hippocampus, with parallel increases in cortex. The effect persisted for several hours and was reproducible across experimental conditions.

BDNF protein levels also increased, on a slightly delayed timescale consistent with translation kinetics. Downstream effects on synaptic plasticity markers — TrkB phosphorylation, ERK pathway activation — were observed. The mechanism upstream of BDNF transcription wasn't fully resolved, but the convergence of the data on BDNF as a key downstream node was clear.

The Dopaminergic Side

The other major mechanistic thread in the Semax literature involves catecholaminergic systems. Eremin, Gulyaeva, and colleagues showed Semax modulated dopaminergic activity in the prefrontal cortex and striatum, with patterns somewhat reminiscent of psychostimulant drugs but without the classic monoamine reuptake inhibition profile.

The behavioral correlates of these effects were studied in rat learning and memory paradigms. Semax-treated animals showed faster acquisition in passive avoidance learning, improved performance in maze tasks, and altered exploratory behavior in open-field tests. The effects were dose-dependent within a relatively narrow window — at higher doses, the cognitive enhancement effects diminished, suggesting a U-shaped dose-response curve common to neurotropic peptides.

The Russian Stroke Trials

The clinical evidence for Semax in humans is concentrated in Russian-language stroke and post-stroke cognitive impairment trials conducted from the late 1990s onward. The trials are typically small (50-200 patients), often single-center, and designed in ways that don't always meet Western Phase III pivotal standards. The reported outcomes are positive — improvements in NIHSS scores, faster neurological recovery, better cognitive performance on follow-up testing.

Independent replication outside Russia has been limited. A few European groups have published work attempting to validate the cognitive findings in animal models with mixed success. The fundamental BDNF effect appears robust across labs. The behavioral and clinical translations are more variable. The lack of Western Phase III trials means Semax remains, in the FDA and EMA frameworks, an unapproved investigational compound — and remains, in Russia, a registered drug with two decades of clinical use.

The Selank Connection

Semax has a sibling. Selank, also developed in the Ashmarin laboratory tradition, is a heptapeptide analog of tuftsin (a tetrapeptide fragment of human IgG with immunomodulatory and anxiolytic activity). Like Semax, it's approved in Russia (for anxiety disorders) and largely unknown in Western pharmacology. The two compounds are sometimes mentioned together in discussions of Russian peptide pharmacology because they share an institutional origin and a similar regulatory profile.

Selank's mechanism is somewhat distinct — it appears to act primarily on serotonergic and GABAergic systems rather than the BDNF axis that dominates Semax's effects. But the broader pharmacological strategy is the same: take a known bioactive peptide fragment, modify it for stability, characterize it in animal models, and develop it through the Russian regulatory pathway. The two drugs are useful examples of how peptide pharmacology can develop in research traditions that don't share the FDA framework.

For Research Use

Semax in research applications is typically dosed at 50-300 µg/kg in rats, with most protocols using intranasal administration to mirror the human dosing route. Plasma half-life of Semax is short — minutes — but the central effects appear to persist much longer than plasma levels would suggest, indicating either sustained CNS exposure via nasal-to-brain transport or downstream effects (like BDNF transcription) that don't require continuous Semax presence to maintain.

For BDNF-modulation experiments specifically, Semax has accumulated enough convergent evidence to be a reasonable positive control compound. For broader behavioral or clinical work, the data is suggestive but the body of independent replication isn't deep enough to support strong claims. The drug is registered in Russia. The molecular biology is reproducible. The translation to other cognitive applications is research, not established pharmacology.

Sources: Ashmarin et al., Russian J Physiol, 1994; Dolotov et al., Brain Research, 2006; Karpenko et al., Neurosci Lett, 2007; Levitskaya et al., Doklady Biological Sciences, 2008; Eremin et al., Neurosci Behav Physiol, 2005; Russian Ministry of Health Semax registration documents, 1994-present.